FDA Panel Backs New mRNA Flu Shot After Policy Reversal

A new flu vaccine that works 27% better than standard shots won unanimous support from FDA advisors, marking a comeback after political interference nearly blocked its review.

The mRNA platform could transform how we fight future flu pandemics.